title: Evaluation of vaccination strategies against infection with feline immunodeficiency virus (FIV) based on recombinant viral vectors expressing FIV Rev and OrfA.
abstract: In recent years it has become clear that cell-mediated immunity is playing a role in the control of lentivirus infections. In particular, cytotoxic T lymphocyte responses have been associated with improved outcome of infection, especially those directed against the regulatory proteins like Rev and Tat, which are expressed early after infection. Therefore, there is considerable interest in lentiviral vaccine candidates that can induce these types of immune responses. In the present study, we describe the construction and characterisation of expression vectors based on recombinant Semliki Forest virus system and modified vaccinia virus Ankara for the expression of feline immunodeficiency virus (FIV) accessory proteins Rev and OrfA. These recombinant viral vectors were used to immunize cats using a prime-boost regimen and the protective efficacy of this vaccination strategy was assessed after challenge infection of immunized cats with FIV.
authors.affiliation: Erasmus MC, Institute of Virology, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
authors.forename: Willem
authors.initials: W
authors.lastname: Huisman
authors.forename: Eefje J A
authors.initials: EJ
authors.lastname: Schrauwen
authors.forename: Edwin
authors.initials: E
authors.lastname: Tijhaar
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Süzer
authors.forename: Suzan D
authors.initials: SD
authors.lastname: Pas
authors.forename: Geert
authors.initials: G
authors.lastname: van Amerongen
authors.forename: Gerd
authors.initials: G
authors.lastname: Sutter
authors.forename: Guus F
authors.initials: GF
authors.lastname: Rimmelzwaan
authors.forename: Albert D M E
authors.initials: AD
authors.lastname: Osterhaus
mesh_terms: D000818:Animals; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D016181:Feline Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D005822:Genetic Vectors; D016089:Immunodeficiency Virus, Feline / Q000276:immunology*; D016233:Immunotherapy, Active / Q000379:methods / Q000662:veterinary*; D012672:Semliki forest virus; D014616:Vaccinia virus; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D014765:Viral Vaccines